Cutaneous Melanoma

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)